Cytokinetics (CYTK) Stock Analysis: AI Score & Alternative Data
CYTK alt-data: job postings climbing, web traffic lagging
Is Cytokinetics a buy right now? The alternative data leans no. This CYTK stock analysis is built on the 25+ alternative data signals AltIndex tracks on Cytokinetics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 33/100: a Sell. The stock trades at $84.87 with a $12B market cap.
The 90-day pressure points: web traffic down 35.0% to 140K monthly visits, and just 39% of employees report a positive business outlook. There are bright spots — job postings up 47.1% to 50 open roles, and headcount (according to LinkedIn) up 6.9% to 779 employees — but not enough to offset the broader weakness.
CYTK’s broader alt-data profile also covers quarterly revenue ($20M), X followers (2K), and sentiment (100/100). Every signal links to its own page with full history, the CYTK technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on CYTK is just below.
Cytokinetics AI Stock Analysis
Cytokinetics (CYTK) is a biotechnology company focused on the discovery, development, and commercialization of novel therapies for people with devastating diseases involving muscle dysfunction and weakness.
Analysis generated June 30, 2026.
Recent Cytokinetics Stock Alerts
|
Cytokinetics | July 9 Insider Alert: Malik Fady Ibraham is selling shares |
|
Cytokinetics | July 3 Gilbert Cisneros (member of U.S. congress) is buying shares |
|
Cytokinetics | June 29 Price is up by 6.2% in the last 24h. |
|
Cytokinetics | June 25 Insider Alert: Malik Fady Ibraham is continuing selling shares |
Cytokinetics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 140K | 35.0% | |
| Job Posts | 50 | 47.1% | |
| LinkedIn Employees | 779 | 6.9% | |
| Employee Recommend | 40 | 0% | |
| Business Outlook | 39 | 0% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 95 | 0% | |
| Stocktwits Mentions | 6 | 200.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 5K | 0.5% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 2K | 0.9% | |
| Youtube Subscribers | 542 | 1.3% | |
| Facebook Followers | 810 | 2.9% | |
| Facebook Engagement | 5 | N/A |
About Cytokinetics (CYTK)
Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
| Price | $84.87 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $12B |
| Year Range | $33 – $87 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Cytokinetics News
View more →
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026July 7 - GlobeNewswire |
|
Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?June 29 - Yahoo Entertainment |
|
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 17 - GlobeNewswire |
|
Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM TreatmentJune 13 - Yahoo Entertainment |
|
Cytokinetics Announces Call for Proposals for Annual Corporate Giving ProgramJune 8 - GlobeNewswire |
|
Cytokinetics Earnings & Financial Performance
View all earnings →Cytokinetics Insider Trading Activity
View all →| Malik Fady Ibraham filed to sell 153,902 shares at $0.0. Jul 7 '26 |
| Lee Sung filed to sell 63,221 shares at $0.0. Jul 1 '26 |
| Blum Robert I filed to sell 377,830 shares at $0.0. Jul 1 '26 |
| Callos Andrew filed to sell 58,555 shares at $0.0. Jul 1 '26 |
| Malik Fady Ibraham filed to sell 153,902 shares at $0.0. Jun 23 '26 |
Cytokinetics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Gilbert Cisneros |
Jul 3, 26 | Buy | $8K+ |
| Lisa McClain |
Aug 13, 25 | Buy | $8K+ |
Stocks Similar to Cytokinetics
See all →
Explore Cytokinetics Data
Frequently Asked Questions: Cytokinetics (CYTK)
Cytokinetics has an AltIndex AI Score of 33/100 (Sell). The score reflects negative alternative data signals. All investments carry risk.
33/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Cytokinetics (CYTK) stock is $84.87 with a market cap of $12B.
As of today, Cytokinetics’s PE (Price to Earnings) ratio is —.
View the latest Cytokinetics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Cytokinetics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The CYTK stock price chart above shows Cytokinetics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Cytokinetics technical analysis for RSI, moving averages, and more.
See the stocks similar to Cytokinetics section on this page for companies in the same industry ranked by market cap and AI Score.
